Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information (Tables)

v3.25.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Profit and Loss From Segments For additional information on the year over year change of segment expenses refer to Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

 

 

(in thousands)

 

Research and development expenses:

 

 

 

 

 

 

Personnel

 

$

39,239

 

 

$

22,375

 

Clinical trials

 

 

22,286

 

 

 

8,302

 

Development services

 

 

16,417

 

 

 

12,486

 

Manufacturing of preclinical and clinical supplies

 

 

15,523

 

 

 

8,498

 

License of intellectual property

 

 

1,523

 

 

 

2,383

 

Other research and development costs (1)

 

 

2,215

 

 

 

1,380

 

General and administration expenses

 

 

27,938

 

 

 

19,236

 

Interest income

 

 

(10,025

)

 

 

(6,985

)

Interest expense

 

 

748

 

 

 

 

Net loss

 

$

115,864

 

 

$

67,675

 

 

(1) Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.